MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Roivant Sciences Ltd

Fechado

SetorSaúde

11.42 -1.89

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.38

Máximo

11.7

Indicadores-chave

By Trading Economics

Rendimento

-278M

-252M

Vendas

-1.4M

7.6M

EPS

-0.29

Margem de lucro

-3,333.884

Funcionários

750

EBITDA

-9.2M

-284M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+38.65% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

313M

7.9B

Abertura anterior

13.31

Fecho anterior

11.42

Sentimento de Notícias

By Acuity

50%

50%

154 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de jul. de 2025, 21:01 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 20:46 UTC

Ganhos

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 de jul. de 2025, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 20:36 UTC

Ganhos

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 de jul. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 de jul. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 20:02 UTC

Conversa de Mercado

Gold Higher to Close Out Week -- Market Talk

18 de jul. de 2025, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 de jul. de 2025, 19:06 UTC

Conversa de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 de jul. de 2025, 18:24 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 de jul. de 2025, 18:19 UTC

Ganhos

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 de jul. de 2025, 18:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 de jul. de 2025, 18:11 UTC

Ganhos

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 de jul. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 de jul. de 2025, 16:29 UTC

Conversa de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 de jul. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 16:04 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 de jul. de 2025, 15:47 UTC

Conversa de Mercado
Ganhos

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparação entre Pares

Variação de preço

Roivant Sciences Ltd Previsão

Preço-alvo

By TipRanks

38.65% parte superior

Previsão para 12 meses

Média 16 USD  38.65%

Máximo 19 USD

Mínimo 12 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Roivant Sciences Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

11 / 11.18Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

154 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

$

Sobre Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.